Kadmon Holdings, Inc.

Passed

Class Action Period:
October 01, 2020 - March 10, 2021

Lead Plaintiff Deadline:
June 02, 2021

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

(i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until June 02, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.